Chemotherapeutic Targeting of Myeloid-derived Suppressor Cells

Overview

Journal Oncoimmunology

Specialty Allergy & Immunology

Date 2014 Mar 22

PMID 24653963

Citations 8

Authors

Darya Alizadeh

Emmanuel Katsanis

Nicolas Larmonier

Affiliations

Soon will be listed here.

Abstract

Myeloid-derived suppressor cells (MDSCs), which expand in cancer-bearing hosts, contribute to the escape of malignant cells from immune destruction and impair the efficacy of immunotherapeutic interventions. We have recently demonstrated that the conventional chemotherapeutic agent doxorubicin selectively eliminates MDSCs, hence promoting the activity of immune effector cells and improving the therapeutic profile of adoptively transferred helper T lymphocytes.

Citing Articles

A Comprehensive Biological and Clinical Perspective Can Drive a Patient-Tailored Approach to Multiple Myeloma: Bridging the Gaps between the Plasma Cell and the Neoplastic Niche.

Solimando A, Vacca A, Ribatti D J Oncol. 2020; 2020:6820241.

PMID: 32508920 PMC: 7251466. DOI: 10.1155/2020/6820241.

Doxorubicin pretreatment enhances FAPα/survivin co-targeting DNA vaccine anti-tumor activity primarily through decreasing peripheral MDSCs in the 4T1 murine breast cancer model.

Geng F, Bao X, Dong L, Guo Q, Guo J, Xie Y Oncoimmunology. 2020; 9(1):1747350.

PMID: 32363118 PMC: 7185204. DOI: 10.1080/2162402X.2020.1747350.

Doxorubicin modulated clock genes and cytokines in macrophages extracted from tumor-bearing mice.

Teixeira A, Biondo L, Silveira L, Lima E, Batatinha H, Diniz T Cancer Biol Ther. 2020; 21(4):344-353.

PMID: 31931676 PMC: 7515505. DOI: 10.1080/15384047.2019.1702400.

NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.

Parihar R, Rivas C, Huynh M, Omer B, Lapteva N, Metelitsa L Cancer Immunol Res. 2019; 7(3):363-375.

PMID: 30651290 PMC: 7906796. DOI: 10.1158/2326-6066.CIR-18-0572.

Trial Watch: Proteasomal inhibitors for anticancer therapy.

Obrist F, Manic G, Kroemer G, Vitale I, Galluzzi L Mol Cell Oncol. 2016; 2(2):e974463.

PMID: 27308423 PMC: 4904962. DOI: 10.4161/23723556.2014.974463.

References

Kodumudi K, Woan K, Gilvary D, Sahakian E, Wei S, Djeu J . A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin Cancer Res. 2010; 16(18):4583-94. PMC: 3874864. DOI: 10.1158/1078-0432.CCR-10-0733. View

Suzuki E, Kapoor V, Jassar A, Kaiser L, Albelda S . Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res. 2005; 11(18):6713-21. DOI: 10.1158/1078-0432.CCR-05-0883. View

Ostrand-Rosenberg S . Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother. 2010; 59(10):1593-600. PMC: 3706261. DOI: 10.1007/s00262-010-0855-8. View

Alizadeh D, Trad M, Hanke N, Larmonier C, Janikashvili N, Bonnotte B . Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer. Cancer Res. 2013; 74(1):104-18. PMC: 3896092. DOI: 10.1158/0008-5472.CAN-13-1545. View

Gabrilovich D, Nagaraj S . Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009; 9(3):162-74. PMC: 2828349. DOI: 10.1038/nri2506. View